Browse ICOSLG

Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF08205 CD80-like C2-set immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Ligand for the T-cell-specific cell surface receptor ICOS. Acts as a costimulatory signal for T-cell proliferation and cytokine secretion; induces also B-cell proliferation and differentiation into plasma cells. Could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function (By similarity).

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0006970 response to osmotic stress
GO:0006972 hyperosmotic response
GO:0007159 leukocyte cell-cell adhesion
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042104 positive regulation of activated T cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0045785 positive regulation of cell adhesion
GO:0046006 regulation of activated T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050798 activated T cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-388841: Costimulation by the CD28 family
R-HSA-168256: Immune System
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ICOSLG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ICOSLG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21098714MelanomaInhibit immunity (T cell function)Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Here we show that human melanomas express inducible T-cell costimulator ligand (ICOS-L/B7H) that can provide costimulation through ICOS for the expansion of activated Tregs maintaining high Foxp3 and CD25 expression as well as a suppressive function.
22850422Ovarian CarcinomaInhibit immunityAccordingly, ICOS(+) Foxp3(+) Treg cells were found to localize in close vicinity of tumor pDCs, and their number directly correlated with the numbers of pDCs in the tumors. Furthermore, pDCs and ICOS(+) Foxp3(+) Treg cells were found to be strong predictors for disease progression in patients with ovarian cancer, with ICOS(+) Treg cell subset being a stronger predictor than total Foxp3(+) Treg cells. These findings suggest an essential role for pDCs and ICOS-L in immunosuppression mediated by ICOS(+) Foxp3(+) Treg cells, leading to tumor progression in ovarian cancer.
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ICOSLG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.24; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ICOSLG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.120.729
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4720.603
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1310.866
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3090.509
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2640.885
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0430.684
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3910.326
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4970.606
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2510.818
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8470.471
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4170.383
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0260.896
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ICOSLG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ICOSLG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ICOSLG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ICOSLG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ICOSLG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ICOSLG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ICOSLG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolICOSLG
Nameinducible T-cell co-stimulator ligand
Aliases KIAA0653; GL50; B7-H2; B7RP-1; B7H2; B7RP1; ICOS-L; CD275; B7-related protein 1; B7 homologue 2; B7 homolog ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ICOSLG collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.